GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

6 competitors in Asthma

TEVAasthma inhalers

PHM.MCLevalbuterol

Phase 3

ALPMYTacrolimus Inhalation Aerosol

Drug Information

Target Indication

Asthma

Clinical Trial

NCT01498679

Last updated: 10/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA10/6/2008

Alisade

Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.

View on EMA

EMA1/11/2008

Avamys

Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

FluoridePhase 3

Dental Caries

Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3

Haemophilus Influenzae Type b

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts